Showing results (201-210 of 254) with videos related to
Sort By:
Pageof 26
The Australasian Journal of Dermatology|December 28, 2020
Mycosis fungoides and Sézary syndrome: Australian clinical practice statementFriyana K Bhabha, Christopher McCormack, Jillian Wells, et al.AIDS (London, England)|May 18, 2017
Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndromeThomas A Rasmussen, James McMahon, J Judy Chang, et al.Blood Advances|October 6, 2020
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphomaConstantine S Tam, Hang Quach, Andrew Nicol, et al.Internal Medicine Journal|May 30, 2026
Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman diseaseDipti Talaulikar, Jun Yen Ng, Adam Bryant, et al.Leukemia & Lymphoma|April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature reviewChan Y Cheah, Michael S Hofman, John F Seymour, et al.Plastic and Reconstructive Surgery|May 9, 2017
Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased RiskAnna Loch-Wilkinson, Kenneth J Beath, Robert John William Knight, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 25, 2007
Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patientsNadege Bercovici, Nacilla Haicheur, Severine Massicard, et al.Cancer Epidemiology|May 16, 2025
Allergic disease and risk of multiple myeloma: A case-control studySimon Cheah, Adrian J Lowe, Nina Afshar, et al.The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.Pageof 26